SEC Form 10-K filed by Rein Therapeutics Inc.
$RNTX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/22/2025 | $10.00 | Buy | H.C. Wainwright |
| 1/28/2025 | $8.00 | Buy | Rodman & Renshaw |
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF)First patient randomized in the United KingdomClinical trial sites now actively enrolling in the United States, Australia, and the United KingdomTwo additional countries expected to be added in the coming months AUSTIN, Texas, June 11, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today provided an update on its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF
Total gross proceeds increased to $57.5 millionOffering consisted solely of common stockProceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028 AUSTIN, Texas, May 18, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten public offering of common stock, including the full exercise of the underwriters' over-allotment option. The financing included new and existing healthcare-focused investors
AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ:RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the pricing of its underwritten public offering of fifty million shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of $50 million, prior to deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 7.5M shares of common stock at the public offering
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
4 - Rein Therapeutics, Inc. (0001420565) (Issuer)
H.C. Wainwright initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $10.00
Rodman & Renshaw initiated coverage of Rein Therapeutics with a rating of Buy and set a new price target of $8.00
DEFA14A - Rein Therapeutics, Inc. (0001420565) (Filer)
DEF 14A - Rein Therapeutics, Inc. (0001420565) (Filer)
PRE 14A - Rein Therapeutics, Inc. (0001420565) (Filer)